Clinical Trials Logo

Clinical Trial Summary

An early phase 1 for pediatric patients with recurrent or progressive CNS malignancies


Clinical Trial Description

This clinical trial is a early phase 1, open label, single center, single arm study of the combination of intravenously administered SGT-53 and irradiation and/or chemotherapy in pediatric patients with recurrent or progressive CNS malignancies. The objective of the study is to establish the safety and feasibility of administration of SGT-53 in conjunction with conventional radiotherapy and/or chemotherapy in children with recurrent or refractory CNS malignancies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03554707
Study type Interventional
Source SynerGene Therapeutics, Inc.
Contact Sabrina Malik
Phone 202-476-5115
Email SaMalik@childrensnational.org
Status Not yet recruiting
Phase Early Phase 1
Start date June 2022
Completion date December 2024